tiprankstipranks
Cipher Pharmaceuticals Buys Dermatology Brand for $89.5M
Company Announcements

Cipher Pharmaceuticals Buys Dermatology Brand for $89.5M

Story Highlights

Cipher Pharmaceuticals (TSE:CPH) has released an update.

Don't Miss Our Christmas Offers:

Cipher Pharmaceuticals has expanded its portfolio with the acquisition of Natroba™, a high-performing dermatology product from ParaPRO, for US$89.5 million. The deal includes the product rights and a seasoned commercial sales team, positioning Cipher for significant market growth in North America and globally. Natroba™, a highly effective treatment for head lice and scabies, is expected to strengthen Cipher’s presence in the dermatology sector.

For further insights into TSE:CPH stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskCipher Pharmaceuticals Faces Setback but Eyes Growth
TheFlyCipher Pharmaceuticals price target lowered to C$17 from C$19 at Stifel
TipRanks Auto-Generated NewsdeskCipher Pharmaceuticals Q3 2024 Results: Growth and Acquisitions
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App